Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2020 00:27 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
June 18, 2020 07:30 ET | Source: BeiGene, LTD.

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
June 12, 2020 02:30 ET | Source: BeiGene, LTD.

BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
June 05, 2020 07:30 ET | Source: BeiGene, LTD.

BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

CAMBRIDGE, Mass. and BEIJING, China, June 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
June 03, 2020 07:15 ET | Source: BeiGene, LTD.

BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma

BEIJING, China and CAMBRIDGE, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
May 29, 2020 08:00 ET | Source: BeiGene, LTD.

BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

- Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VGPR...
May 29, 2020 08:00 ET | Source: BeiGene, LTD.

BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpointCompany to host investor conference call and webcast on ASCO clinical updates on Friday, May 29...
May 26, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

CAMBRIDGE, Mass. and BEIJING, China, May 26, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
May 21, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel

CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on...
May 20, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference

CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right